Mechanistic Positron Emission Tomography Studies of 6-[18F]Fluorodopamine in Living Baboon Heart: Selective Imaging and Control of Radiotracer Metabolism Using the Deuterium Isotope Effect

Abstract: Mechanistic positron emission tomography (PET) studies using the deuterium isotope effect and specific pharmacological intervention were undertaken to examine the behavior of 6-¹⁸F]fluorodopamine (6-¹⁸F]FDA; 1 ) and (?)-6-¹⁸F]fluoronorepinephrine {(?)-6-¹⁸F]FNE; 2 } in the baboon heart. Two regiospecifically deuterated derivatives of 6-¹⁸F]FDA α,α-D₂(3 ) and β,β-D₂ (4 )] were used to assess the contributions of monoamine oxidase (MAO) and dopamine β-hydroxylase, respectively, to the clearance kinetics of 6-¹⁸F]FDA. Compound 3 showed a reduced rate of clearance, consistent with MAO-catalyzed cleavage of the α C-D bond, whereas compound 4 showed no change, indicating that cleavage of the β C-D bond is not a rate-limiting step. Pretreatment with pargyline, an MAO inhibitor, also decreased the rate of clearance. Desipramine and tomoxetine norepinephrine (NE) uptake inhibitors], but not GBR-12909 (a dopamine uptake inhibitor), blocked the uptake of both (?)-6-¹⁸F]FNE and 6-¹⁸F]FDA, with (?)-6-¹⁸F]FNE showing a higher degree of blockade. Chiral HPLC demonstrated that 6-¹⁸F]FDA is stereoselectively converted to (?)-6-¹⁸F]FNE in vivo in the rat heart. These studies demonstrate that (a) the more rapid clearance of 6-¹⁸F]FDA relative to (?)-6-¹⁸F]FNE can be largely accounted for by metabolism by MAO; (b) selective deuterium substitution can be used to protect a radiotracer from metabolism in vivo and to favor a particular pathway; (c) 6-¹⁸F]FDA and (?)-6-¹⁸F]FNE share the NE transporter; (d) 6-¹⁸F]FDA is stereoselectively converted to (?)-6-¹⁸F]FNE in vivo; and (e) the profile of radioactivity in the heart for 6-¹⁸F]FDA is complex, probably including labeled metabolites as well as neuronal and nonneuronal uptake.